| 1. |
- Fathi, Kambiz, et al.
(författare)
-
ALMA FOLLOWS STREAMING OF DENSE GAS DOWN TO 40 PC FROM THE SUPERMASSIVE BLACKHOLE IN NGC 1097
- 2013
-
Ingår i: Astrophysical Journal Letters. - 2041-8205. ; 770:2, s. L27-
-
Tidskriftsartikel (refereegranskat)abstract
- We present a kinematic analysis of the dense gas in the central 200 parsecs of thenearby galaxy NGC1097, based on Cycle 0 observations with the Atacama LargeMillimeter/sub-millimeter Array (ALMA). We use the HCN(4-3) line to trace the densest interstellar molecular gas (nH2 ~ 10^8 cm-3), and quantify its kinematics by means of Fourier decomposition. We find a striking similarity between the ALMA kinematic data and the analytic spiral in ow model that we have previously constructed based onionized gas velocity fields on larger scales. We are able to follow dense gas streamingdown to 40 pc distance from the supermassive black hole in this Seyfert 1 galaxy. In order to fulll marginal stability, we deduce that the dense gas is conned to a very thin disc, with 6.0+2.2-2.7 10^6 Msun dynamical mass inside a radius of 40 pc. Finally, we derive a dense gas in ow rate of 0.09Msun yr-1 at 40 pc radius. Combined with previous valuesfrom the H and CO gas, we calculate a combined molecular and ionized gas in ow rateof 0.2Msun yr-1 at 40 pc distance from the central supermassive black hole of NGC1097.
|
|
| 2. |
- Izumi, Takuma, et al.
(författare)
-
Submillimeter ALMA Observations of the Dense Gas in the Low-Luminosity Type-1 Active Nucleus of NGC 1097
- 2013
-
Ingår i: Publications of the Astronomical society of Japan. - : Oxford University Press (OUP). - 0004-6264 .- 2053-051X. ; 65:5
-
Tidskriftsartikel (refereegranskat)abstract
- We present the first 100 pc scale view of the dense molecular gas in the central similar to 1.3 kpc of the type-1 Seyfert NGC 1097, traced by HCN (J = 4-3) and HCO+ (J = 4-3) lines afforded with ALMA band 7. This galaxy shows significant HCN enhancement with respect to HCO+ and CO in the low-J transitions, which seems to be a common characteristic in AGN environments. Using the ALMA data, we consider the characteristics of the dense gas around this AGN, and search for the mechanism of HCN enhancement. We find a high HCN (J = 4-3) to HCO+ (J = 4-3) line ratio in the nucleus. The upper limit of the brightness temperature ratio of HCN (nu(2) = 1(1f), J = 4-3) to HCN (J = 4-3) is 0.08, which indicates that IR pumping does not significantly affect the pure rotational population in this nucleus. We also find a higher HCN (J = 4-3) to CS (J = 7-6) line ratio in NGC 1097 than in starburst galaxies, which is more than 12.7 on the brightness temperature scale. Combined with similar observations from other galaxies, we tentatively suggest that this ratio appears to be higher in AGN-host galaxies than in pure starburst ones, similar to the widely used HCN to HCO+ ratio. LTE and non-LTE modeling of the observed HCN and HCO+ lines using J = 4-3 and 1-0 data from ALMA, and J = 3-2 data from SMA, reveals a high HCN to HCO+ abundance ratio (5 <= [HCN]/[HCO+] <= 20: non-LTE analysis) in the nucleus, and that the high-J lines (J = 4-3 and 3-2) are emitted from dense (10(4.5) cm(-3) <= n(H2) <= 10(6) cm(-3)), hot (70 K <= T-kin <= 550 K) regions. Finally we propose that high-temperature chemistry is more plausible to explain the observed enhanced HCN emission in NGC 1097 than pure gas-phase PDR/XDR chemistry.
|
|
| 3. |
- Visvanathan, Sudha, et al.
(författare)
-
The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial.
- 2010
-
Ingår i: Pediatric rheumatology online journal. - : Springer Science and Business Media LLC. - 1546-0096. ; 8:1
-
Tidskriftsartikel (refereegranskat)abstract
- ABSTRACT: BACKGROUND: We evaluated the effect of infliximab on markers of inflammation in patients with juvenile idiopathic arthritis (JIA). METHODS: In this randomized, placebo-controlled substudy, 122 patients with JIA received infliximab 3 mg/kg + methotrexate (MTX)(n = 60) or placebo + MTX (n = 62) at weeks 0, 2, and 6. At week 14, patients receiving placebo + MTX crossed over to infliximab 6 mg/kg + MTX; patients receiving infliximab 3 mg/kg + MTX continued treatment through week 44. Sera and plasma from eligible patients receiving infliximab 3 mg/kg + MTX (n = 34) and receiving placebo→infliximab 6 mg/kg +MTX (n = 38) were collected at weeks 0, 2, 14, 16, 28, and 52 and analyzed for inflammatory markers (IL-6, IL-12p40, ICAM-1, MMP-3, VEGF, TNF-α, and CRP). RESULTS: At week 2, decreases from baseline in IL-6, ICAM-1, MMP-3, TNF-α, and CRP were greater with infliximab versus placebo treatment, and with the exception of CRP, these differences were generally maintained through week 14. The decreases from baseline to week 52 in IL-6, ICAM-1, VEGF, MMP-3, and CRP and increases in IL-12p40 levels were larger in patients receiving placebo→infliximab 6 mg/kg +MTX versus infliximab 3 mg/kg + MTX treatment. Patients receiving infliximab 3 mg/kg+MTX who achieved an American College of Rheumatology Pediatric 30 (ACR-Pedi-30) response had significantly larger decreases from baseline in ICAM-1 (p = 0.0105) and MMP-3 (p = 0.0253) at week 2 and in ICAM-1 (p = 0.0304), MMP-3 (p = 0.0091), and CRP (p = 0.0011) at week 14 versus ACR-Pedi-30 nonresponders. CONCLUSION: Infliximab + MTX attenuated several inflammatory markers in patients with JIA; larger decreases in ICAM-1, MMP-3, and CRP levels were observed in ACR-Pedi-30 responders versus nonresponders. TRIAL REGISTRATION: NCT00036374.
|
|
